Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy
  • Other

219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews pediatric psychologist Natalie Truba, PhD, on the psychological aspects of gene therapy in neuromuscular disease.

OtherGene Therapy PlatformRead full story

pharminent April 7, 2026 (Last updated: April 7, 2026)

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews pediatric psychologist Natalie Truba, PhD, on the psychological aspects of gene therapy in neuromuscular disease.

OtherGene Therapy PlatformRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Gilead strikes again, penning $5bn deal to buy Tubulis
Next: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis

Related Stories

  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026
  • Other

225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator

pharminent May 18, 2026
  • Other

Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies

pharminent May 18, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.